Liquid biopsy: what blood-based cancer screening can and can't do yet

Liquid biopsy technology, detecting fragments of tumor DNA circulating in blood, represents a genuinely significant technical achievement, and multi-cancer early detection blood tests built on this technology — designed to screen for signals from many different cancer types through a single blood draw — have generated real, warranted excitement precisely because a single test screening broadly across cancer types would be a meaningful advance over today's approach of separate, cancer-specific screening tests each covering only one cancer type.

Current-generation multi-cancer detection tests carry specific, well-documented limitations worth understanding clearly rather than assuming the technology has already delivered on its full eventual promise: sensitivity varies considerably by cancer type and cancer stage, generally detecting more advanced-stage cancers more reliably than early-stage disease — which is a genuine limitation given that early detection, not late detection, is the entire point of a screening test in the first place.

A positive result on a current multi-cancer detection test also doesn't specify a precise cancer type or location with full certainty, generally requiring meaningful additional diagnostic workup to actually localize and confirm any signal detected — meaning a positive result functions more as a trigger for further, more specific investigation than as a complete diagnostic answer on its own, a genuinely different experience for a patient than a more targeted, established screening test that points toward a specific organ system directly.

Given these current limitations, major medical organizations have generally positioned multi-cancer detection blood tests as a complement to, rather than a replacement for, established guideline-recommended screening (mammography, colonoscopy, and others) at this point in the technology's development — patients considering one of these tests, generally available through direct-to-consumer or physician-ordered channels, are well served by discussing realistic expectations with a physician rather than treating a clean result as a reason to forgo established, guideline-recommended screening that remains the more validated approach for its respective cancer type.